New synthesis and promising neuroprotective role in experimental ischemic stroke of ONO-1714.

Abstract

In an experimental permanent stroke model, we report here the contribution of ONO-1714 to brain damage prevention. Daily drug administration, twenty-one days prior to and two days after an experimental infarct, was performed by using mini-osmotic pumps (ALZET). Infarct volumes were assessed by image analysis of sequential coronal brain 1 mm(3) sections stained following the 2,3,5-triphenyltetrazolium chloride histological staining technique. Results of this study provide evidence of a significant reduction of the brain lesion size, suggesting ONO-1714 as a potential neuroprotective agent in stroke patients. ONO-1714 was prepared in our laboratory following a procedure which resulted in the supply of the desired compound in an easy and excellent yield.

• Authors: Andrea Pozo-Rodrigálvarez, Ana Gradillas, Julia Serrano, Ana Patricia Fernández, Ricardo Martínez-Murillo, Javier Pérez-Castells
• Journal: European journal of medicinal chemistry (Eur J Med Chem) Vol. 54 Pg. 439-46 (Aug 2012) ISSN: 1768-3254 [Electronic] France
• PMID: 22703704 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Chemical References

• 7-chloro-3-imino-5-methyl-2-azabicyclo(4.1.0)heptane
• Amidines
• Heterocyclic Compounds, 2-Ring
• Neuroprotective Agents

Topics

• Amidines (administration & dosage, chemical synthesis, pharmacology)
• Animals
• Brain Ischemia (complications)
• Chemistry Techniques, Synthetic
• Heterocyclic Compounds, 2-Ring (administration & dosage, chemical synthesis, pharmacology)
• Infusion Pumps
• Male
• Mice
• Myocardial Infarction (complications, pathology)
• Neuroprotective Agents (administration & dosage, chemical synthesis, pharmacology)
• Stroke (etiology, pathology, prevention & control)